Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ICMT | O60725 | 13/20 | 0.41 |
| ▸ | FNTA | P49354 | 2/20 | 0.39 |
| ▸ | FNTB | P49356 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21697739 | 0.89 | MAPT (0.62) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL20218756 | 0.84 | MAPT (0.50) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL21697758 | 0.77 | MAPT (0.60) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL21697713 | 0.74 | MAPT (0.57) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL21082128 | 0.74 | MAPT (0.57) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL8012020 | 0.74 | MAPT (0.54) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL20843594 | 0.73 | MAPT (0.53) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL2456586 | 0.73 | MAPT (0.64) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL20218789 | 0.73 | MAPT (0.64) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL2456570 | 0.73 | MAPT (0.64) | MAPTALDH1A1MEN1TRPA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10314802-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10314802-B2 | Isoprenyl compounds and methods thereof | ALOX15B, ALOX15, ALOX5 | MAPT 4014/4885ALDH1A1 882/4885MEN1 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.